Gastrointestinal stromal tumour – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:04:27 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Gastrointestinal stromal tumour – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors. https://clinicaltrials.eu/trial/a-study-of-belzutifan-and-lenvatinib-for-patients-with-von-hippel-lindau-disease-associated-tumors-or-other-specific-solid-tumors/ Thu, 30 Apr 2026 13:08:57 +0000 https://clinicaltrials.eu/trial/a-study-of-belzutifan-and-lenvatinib-for-patients-with-von-hippel-lindau-disease-associated-tumors-or-other-specific-solid-tumors/ This study focuses on individuals with various types of cancer, including Renal Cell Carcinoma, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer, Esophageal Squamous Cell Carcinoma, and Pancreatic Neuroendocrine Tumor. It also includes people with Advanced Pheochromocytoma/Paraganglioma, Advanced Gastrointestinal Stromal Tumor, and certain types of Colorectal Cancer, Endometrial Cancer, or Solid Tumors that have specific genetic changes called HIF-2α related genetic alterations. Additionally, the research involves patients with von Hippel-Lindau Disease-Associated Tumors, which are tumors caused by a specific genetic condition. The purpose of the study is to evaluate the long-term effectiveness and safety of certain treatments.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

]]> Study of DCC-3116 and ripretinib combination therapy in patients with advanced gastrointestinal stromal tumor (GIST) https://clinicaltrials.eu/trial/study-of-dcc-3116-and-ripretinib-for-patients-with-advanced-gastrointestinal-stromal-tumor-gist/ Wed, 29 Apr 2026 15:04:38 +0000 https://clinicaltrials.eu/trial/study-of-dcc-3116-and-ripretinib-for-patients-with-advanced-gastrointestinal-stromal-tumor-gist/ This study focuses on patients with advanced gastrointestinal stromal tumor (GIST), which is a rare type of cancer that occurs in the digestive tract. The study will test a combination of two medications: DCC-3116 and ripretinib (also known as QINLOCK). Both medications are taken by mouth in tablet form.

The purpose of this research is to evaluate how well patients with advanced GIST respond to the combination treatment of these medications. The study will look at patients whose cancer has either gotten worse after treatment with another medication called imatinib, or who could not tolerate imatinib treatment.

During the study, participants will receive both medications and will be monitored for how their cancer responds to the treatment. The doctors will track any changes in the tumor size and watch for any side effects that may occur. The study will also measure how the medications work in the body and how long the treatment effects last. Regular medical check-ups and scans will be performed to evaluate the treatment’s effectiveness.

]]> Study of Avelumab and Axitinib for Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors After Standard Therapy Failure https://clinicaltrials.eu/trial/study-of-avelumab-and-axitinib-for-patients-with-unresectable-or-metastatic-gastrointestinal-stromal-tumors-after-standard-therapy-failure/ Wed, 29 Apr 2026 15:04:00 +0000 https://clinicaltrials.eu/trial/study-of-avelumab-and-axitinib-for-patients-with-unresectable-or-metastatic-gastrointestinal-stromal-tumors-after-standard-therapy-failure/ This clinical trial is focused on studying a type of cancer known as Gastrointestinal Stromal Tumors (GIST). These tumors occur in the digestive tract and can be challenging to treat, especially when they cannot be removed by surgery or have spread to other parts of the body. The study is testing a combination of two medications, avelumab and axitinib, to see how effective they are in treating patients with GIST who have not responded to standard treatments.

Avelumab is a type of medication known as an antibody, which helps the immune system recognize and attack cancer cells. It is given through an infusion, which means it is delivered directly into the bloodstream through a vein. Axitinib is a medication taken in tablet form that works by blocking certain proteins that help cancer cells grow. Together, these medications aim to slow down or stop the growth of the tumors.

The purpose of the study is to evaluate how well this combination of medications works in keeping the cancer from getting worse. Participants in the study will receive the treatment over a period of time and will be monitored regularly to assess the response of their tumors to the treatment. The study will also look at the overall survival of participants and any side effects they may experience. This research hopes to provide new insights into treating GIST and improve outcomes for patients with this challenging condition.

]]> Study to Find the Right Dose and Safety of Lutetium (177Lu) Edotreotide and Arginine-Lysine in Children with Somatostatin Receptor-Positive Tumors https://clinicaltrials.eu/trial/study-to-find-the-right-dose-and-safety-of-lutetium-177lu-edotreotide-and-arginine-lysine-in-children-with-somatostatin-receptor-positive-tumors/ Wed, 29 Apr 2026 15:03:43 +0000 https://clinicaltrials.eu/trial/study-to-find-the-right-dose-and-safety-of-lutetium-177lu-edotreotide-and-arginine-lysine-in-children-with-somatostatin-receptor-positive-tumors/ This clinical trial is focused on studying the treatment of children with somatostatin receptor-positive tumors, which are a type of solid tumor or lymphoma that shows a specific marker called the somatostatin receptor. These tumors can include various types such as neuroendocrine tumors, lymphoma, and central nervous system tumors. The treatment being tested is called lutetium Lu 177 edotreotide, a targeted radiopharmaceutical therapy. This therapy involves using a radioactive substance to target and treat the tumors. Additionally, an arginine-lysine solution is used to support the treatment process.

The purpose of the study is to determine the appropriate dose of lutetium Lu 177 edotreotide for children, based on its safety and how it moves through the body. The study will involve giving the treatment to participants and monitoring them to see how their bodies respond. This includes checking for any side effects and measuring how the treatment is absorbed by the body. The study will also look at how effective the treatment is in reducing the size of the tumors.

Participants in the study will receive the treatment through an intravenous infusion, which means it will be given directly into a vein. The study will take place over several cycles, with regular check-ups to monitor the participants’ health and the progress of the treatment. The goal is to find the safest and most effective dose for treating these types of tumors in children. The study is expected to continue for several years to gather enough information to make informed decisions about the treatment’s use in the future.

]]> Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-2927088-for-patients-with-advanced-solid-tumors-with-her2-mutations/ Wed, 29 Apr 2026 15:03:10 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-2927088-for-patients-with-advanced-solid-tumors-with-her2-mutations/ This clinical trial is focused on studying the effects of a new treatment for people with advanced solid tumors that have a specific change in their genes known as a HER2 mutation. The treatment being tested is a medication called BAY 2927088, which is taken as a coated tablet. This medication is a type of drug known as a reversible tyrosine kinase inhibitor, which works by blocking certain proteins that help cancer cells grow.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

]]> Study on the Effectiveness of Imatinib for Patients with Intermediate-Risk Gastrointestinal Stromal Tumor and High Genomic Grade Index https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-imatinib-for-patients-with-intermediate-risk-gastrointestinal-stromal-tumor-and-high-genomic-grade-index/ Wed, 29 Apr 2026 15:01:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-imatinib-for-patients-with-intermediate-risk-gastrointestinal-stromal-tumor-and-high-genomic-grade-index/ This clinical trial is focused on studying the effectiveness of a treatment for a type of cancer known as gastrointestinal stromal tumor (GIST). The treatment being tested is a medication called Imatinib, which is taken orally. Imatinib is a type of drug known as a protein-tyrosine kinase inhibitor, which works by blocking certain proteins that can promote the growth of cancer cells.

The purpose of this study is to evaluate how well Imatinib works in preventing the return of cancer in patients who have an intermediate-risk GIST with a high-risk Genomic Grade Index. Participants in the study will be randomly assigned to receive either Imatinib or a placebo. The study will monitor the participants over a period of time to see if the cancer returns and to assess their overall health and quality of life.

Throughout the study, participants will undergo regular check-ups, including imaging tests like CT scans, to track their health status. The study aims to determine the rate of cancer recurrence over two years and to gather information on the overall survival and well-being of the participants. This research will help in understanding the potential benefits of using Imatinib as an additional treatment for patients with this specific type of cancer.

]]> Study of IDRX-42 for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST) https://clinicaltrials.eu/trial/study-of-idrx-42-for-patients-with-metastatic-or-unresectable-gastrointestinal-stromal-tumors-gist/ Wed, 29 Apr 2026 15:01:01 +0000 https://clinicaltrials.eu/trial/study-of-idrx-42-for-patients-with-metastatic-or-unresectable-gastrointestinal-stromal-tumors-gist/ This clinical trial is focused on studying a type of cancer known as gastrointestinal stromal tumors (GIST), which can be either metastatic, meaning it has spread to other parts of the body, or unresectable, meaning it cannot be removed with surgery. The treatment being tested in this study is a new medication called IDRX-42, which is a small molecule designed to specifically target and inhibit certain proteins known as tyrosine kinases that are involved in the growth of cancer cells.

The purpose of the study is to determine the best dose and schedule for taking IDRX-42 and to further understand its safety and effectiveness in treating patients with GIST. Participants in the study will receive IDRX-42 in the form of either tablets or capsules, which are taken orally. The study will be conducted in phases, starting with determining the maximum dose that can be tolerated and then moving on to assess the safety and potential benefits of the treatment.

Throughout the study, participants will be monitored for any side effects and the impact of the treatment on their cancer. The study aims to provide valuable information on how IDRX-42 can be used to help patients with GIST, potentially offering a new treatment option for those with this challenging condition. Participants will be required to attend regular visits for assessments and to follow the study’s treatment plan. The study is expected to continue until 2026, with the goal of gathering comprehensive data on the use of IDRX-42 in treating GIST.

]]> Study on the Effectiveness of Lenvatinib for Patients with Advanced Gastrointestinal Stromal Tumors After Imatinib and Sunitinib Treatment Failure https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-lenvatinib-for-patients-with-advanced-gastrointestinal-stromal-tumors-after-imatinib-and-sunitinib-treatment-failure/ Wed, 29 Apr 2026 15:00:19 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-lenvatinib-for-patients-with-advanced-gastrointestinal-stromal-tumors-after-imatinib-and-sunitinib-treatment-failure/ This clinical trial is focused on studying a type of cancer known as Gastrointestinal Stromal Tumor (GIST), which is a rare cancer affecting the digestive tract. The study is specifically for patients whose cancer has spread to other parts of the body or is locally advanced, meaning it has grown significantly in its original location. The trial is testing the effectiveness of a medication called lenvatinib, which is taken in the form of hard capsules. Lenvatinib is a type of drug known as a tyrosine kinase inhibitor, which works by blocking certain proteins that promote cancer cell growth. The study will compare lenvatinib to a placebo, which is a substance with no active medication, to see how well it works in patients who have not responded to previous treatments with other drugs called imatinib and sunitinib.

The purpose of this study is to evaluate how well lenvatinib can control the growth of the cancer compared to a placebo. Participants in the study will be randomly assigned to receive either lenvatinib or the placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The trial will last for a period of time during which participants will take the medication and have regular check-ups to monitor their health and the progress of their cancer.

Throughout the study, the main focus will be on measuring how long patients can live without their cancer getting worse, which is known as progression-free survival. Other aspects being studied include overall survival, which is the length of time patients live after starting the trial, and the objective response rate, which measures how many patients experience a significant reduction in their cancer. The study will also assess the quality of life of participants and monitor any side effects they may experience. This information will help determine the potential benefits and risks of using lenvatinib for treating advanced GIST.

]]> Study on Continuing or Stopping Imatinib in Patients with Advanced or Metastatic Gastrointestinal Stromal Tumors After 10 Years of Treatment https://clinicaltrials.eu/trial/study-on-continuing-or-stopping-imatinib-in-patients-with-advanced-or-metastatic-gastrointestinal-stromal-tumors-after-10-years-of-treatment/ Wed, 29 Apr 2026 15:00:07 +0000 https://clinicaltrials.eu/trial/study-on-continuing-or-stopping-imatinib-in-patients-with-advanced-or-metastatic-gastrointestinal-stromal-tumors-after-10-years-of-treatment/ This clinical trial is focused on studying the treatment of Gastrointestinal Stromal Tumors (GISTs), which are a type of tumor that occurs in the digestive tract. The study involves the use of a medication called imatinib, also known by its brand name Glivec. Imatinib is a drug that has been used to treat patients with GISTs for many years. The purpose of this study is to evaluate whether continuing or stopping imatinib treatment after at least 10 years is more beneficial for patients whose disease has been controlled with the medication.

Participants in the study will be randomly assigned to one of two groups. One group will continue taking imatinib, while the other group will stop taking the medication. The study will monitor the health of participants over a period of time to see if there is any difference in the progression of the disease between the two groups. This will help researchers understand the best approach to managing long-term treatment for patients with advanced or metastatic GISTs.

The study will last for several years, and participants will have regular follow-up visits to check on their health and the status of their disease. The main goal is to determine if stopping the medication after a long period of use is safe and effective, or if continuing the treatment provides better outcomes for patients. This information will be valuable in guiding future treatment decisions for individuals with GISTs.

]]> Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib https://clinicaltrials.eu/trial/study-comparing-ripretinib-and-sunitinib-for-patients-with-advanced-gastrointestinal-stromal-tumors-previously-treated-with-imatinib/ Wed, 29 Apr 2026 14:59:51 +0000 https://clinicaltrials.eu/trial/study-comparing-ripretinib-and-sunitinib-for-patients-with-advanced-gastrointestinal-stromal-tumors-previously-treated-with-imatinib/ This clinical trial is focused on studying a type of cancer known as Gastrointestinal Stromal Tumors (GIST). The study is comparing the effectiveness and safety of a new treatment called DCC-2618 with an existing medication named Sunitinib. Patients participating in this study have previously been treated with another medication called Imatinib.

The purpose of the study is to evaluate how well DCC-2618 works in patients with advanced GIST who have already received treatment with Imatinib. During the study, participants will be randomly assigned to receive either DCC-2618 or Sunitinib. The study will monitor the progression of the disease and any side effects experienced by the participants. The treatment will be administered orally, meaning it will be taken by mouth in the form of capsules or tablets.

This study aims to provide valuable information about the potential benefits and risks of using DCC-2618 as a treatment option for patients with advanced GIST. The results will help determine if DCC-2618 can be a more effective treatment compared to Sunitinib for patients who have already been treated with Imatinib.

]]> Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST) https://clinicaltrials.eu/trial/study-on-the-effect-of-extending-imatinib-treatment-from-three-to-five-years-for-patients-with-high-risk-gastrointestinal-stromal-tumor-gist/ Wed, 29 Apr 2026 14:58:43 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-extending-imatinib-treatment-from-three-to-five-years-for-patients-with-high-risk-gastrointestinal-stromal-tumor-gist/ This clinical trial is focused on studying a type of cancer known as gastrointestinal stromal tumor (GIST). GIST is a tumor that occurs in the digestive tract, and this study is particularly interested in patients who have a high risk of the tumor coming back after surgery. The treatment being tested is a medication called imatinib, which is taken in the form of film-coated tablets known as Glivec. Imatinib is a chemical substance that helps to prevent the growth of cancer cells.

The purpose of the study is to see if taking imatinib for five years, instead of the usual three years, can help patients stay free from the tumor for a longer time. Patients who have already completed three years of imatinib treatment after surgery will be randomly assigned to either continue taking the medication for an additional two years or to stop the treatment. This will help researchers understand if the extended treatment period offers better protection against the tumor returning.

Throughout the study, participants will have regular check-ups, including scans like CT or MRI, to monitor their health and check for any signs of the tumor coming back. These check-ups will occur every six months for the first five years and then once a year. The study will also look at overall survival, survival specific to GIST, safety, and quality of life for the participants. The trial is expected to continue until the end of 2030.

]]> Study on Imatinib and Atezolizumab for Patients with Advanced Gastrointestinal Stromal Tumors After Standard Treatments Fail https://clinicaltrials.eu/trial/study-on-imatinib-and-atezolizumab-for-patients-with-advanced-gastrointestinal-stromal-tumors-after-standard-treatments-fail/ Wed, 29 Apr 2026 14:25:26 +0000 https://clinicaltrials.eu/trial/study-on-imatinib-and-atezolizumab-for-patients-with-advanced-gastrointestinal-stromal-tumors-after-standard-treatments-fail/ This clinical trial is focused on studying a type of cancer known as gastrointestinal stromal tumors (GIST). These tumors can be locally advanced, meaning they have grown significantly in the area where they started, or they can be unresectable, which means they cannot be removed with surgery. They can also be metastatic, indicating that the cancer has spread to other parts of the body. The study is investigating the effectiveness of a treatment that combines two medications: imatinib and atezolizumab. Imatinib is a medication that has been used to treat GIST, while atezolizumab is a type of drug known as an immunotherapy, which helps the body’s immune system fight cancer.

The purpose of this study is to compare the effectiveness of resuming treatment with imatinib alone versus combining it with atezolizumab in patients whose GIST has not responded to standard treatments. Participants in the study will be randomly assigned to one of two groups. One group will receive imatinib alone, and the other group will receive both imatinib and atezolizumab. The study will last for a period of up to 12 months, during which the participants will receive their assigned treatments and be monitored regularly to assess the progress of their disease.

Throughout the study, researchers will be looking at several outcomes, including how long patients live without their disease getting worse, the overall response to the treatment, and the quality of life of the participants. The study aims to provide valuable information on whether the combination of imatinib and atezolizumab offers better outcomes for patients with advanced GIST compared to imatinib alone. Participants will receive their treatments either orally, in the case of imatinib, or through an intravenous infusion, in the case of atezolizumab.

]]> Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors https://clinicaltrials.eu/trial/study-of-cgt9486-and-sunitinib-for-patients-with-advanced-gastrointestinal-stromal-tumors/ Wed, 29 Apr 2026 14:25:11 +0000 https://clinicaltrials.eu/trial/study-of-cgt9486-and-sunitinib-for-patients-with-advanced-gastrointestinal-stromal-tumors/ This clinical trial is focused on studying a type of cancer known as gastrointestinal stromal tumors (GIST). These tumors occur in the digestive tract and can be challenging to treat, especially when they are advanced or have spread to other parts of the body. The study is comparing two treatments: a combination of two medications, CGT9486 and Sunitinib, against Sunitinib alone. CGT9486 is a new medication that works by blocking certain proteins that help cancer cells grow, while Sunitinib is an existing treatment that also targets cancer cell growth.

The purpose of this study is to determine how effective the combination of CGT9486 and Sunitinib is compared to Sunitinib alone in treating patients with GIST. Participants in the study will be randomly assigned to receive either the combination treatment or Sunitinib by itself. The study will monitor the progress of the disease and any side effects over a period of time to see which treatment works better.

Participants will take the medications orally, meaning they will swallow them in the form of tablets or capsules. The study will last for a maximum of 34 weeks, during which time the health and progress of the participants will be closely monitored by the research team. The goal is to find out if the new combination treatment can help control the disease more effectively than the current standard treatment.

]]> Study of Ripretinib vs Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumor with Specific KIT Exon Mutations Previously Treated with Imatinib https://clinicaltrials.eu/trial/study-of-ripretinib-vs-sunitinib-for-patients-with-advanced-gastrointestinal-stromal-tumor-with-specific-kit-exon-mutations-previously-treated-with-imatinib/ Wed, 29 Apr 2026 14:23:29 +0000 https://clinicaltrials.eu/trial/study-of-ripretinib-vs-sunitinib-for-patients-with-advanced-gastrointestinal-stromal-tumor-with-specific-kit-exon-mutations-previously-treated-with-imatinib/ This clinical trial is focused on studying a type of cancer known as Advanced Gastrointestinal Stromal Tumor (GIST). This is a rare cancer that occurs in the digestive tract, most commonly in the stomach or small intestine. The study is comparing two treatments: Ripretinib and Sunitinib. Ripretinib, also known by its code name DCC-2618, is a medication that targets specific proteins involved in cancer growth. Sunitinib is another medication used to treat certain types of cancer by blocking the action of proteins that promote tumor growth.

The purpose of the study is to compare the effectiveness of Ripretinib and Sunitinib in patients with advanced GIST who have specific genetic changes called KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations. These mutations are changes in the DNA that can affect how cancer grows and responds to treatment. Patients in this study have previously been treated with another medication called Imatinib but need further treatment due to the progression of their disease.

Participants in the study will be randomly assigned to receive either Ripretinib or Sunitinib. The study will last for a period of up to 24 months, during which time the patients will take the medication orally in the form of tablets or capsules. The progress of the disease will be monitored through regular medical assessments to determine how well the treatment is working. The study aims to provide valuable information on which treatment may be more effective for patients with this specific type of GIST.

]]> GIST Cancer UK https://clinicaltrials.eu/organisation/gist-cancer-uk/ Wed, 29 Apr 2026 13:34:18 +0000 https://clinicaltrials.eu/organisation/gist-cancer-uk/ GIST Cancer UK is an organization dedicated to supporting patients with Gastro-Intestinal Stromal Tumour (GIST) cancer and funding research into this rare disease. They offer a wide range of services to help individuals affected by GIST, including a confidential helpline and online forums for exchanging information and support among patients and caregivers. In addition to direct patient support, GIST Cancer UK actively promotes research for more effective treatments. They encourage donations and fundraising efforts and emphasize the importance of tissue donation to The National GIST Biobank for essential research.

]]>